Last updated: April 25, 2026
What is CN107075516 and what does it protect?
CN107075516 is a China patent publication that protects a defined pharmaceutical invention through a set of product and method claims that hinge on specific structural or compositional limitations and on defined therapeutic use conditions. The protected subject matter is delineated by claim dependencies (independent claim scope is bounded by its own limitations; dependent claims narrow the protected embodiments through additional technical features).
Patent coverage in practical terms: CN107075516 is positioned as a “core composition and/or formulation plus use” patent rather than a broad platform patent. The claim set typically structures protection into:
- Drug substance (active) and/or composition/formulation defined by chemical structure and/or component ratios and process constraints.
- Manufacture methods tying the claimed composition to manufacturing steps and parameter windows.
- Therapeutic uses that restrict infringement to defined indications, dosing regimens, or treatment contexts.
Because the protection boundary is claim-driven, infringement risk and freedom-to-operate depend on whether a product falls within the literal claim scope and whether any design-around shifts key structural or parameter limitations outside the claim.
What does the claim set look like (scope architecture)?
CN107075516’s scope is organized around independent claims, then narrowed by dependent claims. The landscape effect is that later-generation competitors can often enter by switching one or more of the limiting features captured in dependent claim narrowing, while still staying close to the independent claim boundaries.
Claim scope architecture
| Claim layer |
Typical scope characteristic |
Landscape implication |
| Independent claims |
Broadest technically allowable scope under the patent’s defining limitations (core structure/composition/use) |
Sets the main “no-go zone” for generic or biosimilar entry |
| Dependent claims |
Add narrower features (specific substituents, excipient sets, formulation ranges, dosing windows) |
Creates entry points for design-arounds if key added features are avoided |
| Method-of-treatment claims |
Tie the drug to a patient population/indication and regimen |
Protects only labeled or medically practiced use within claim constraints |
What are the technical and legal levers that define infringement?
For a China drug patent, claim construction in practice tends to turn on a small number of levers. For CN107075516, those levers are the claim-specific limitations that define the inventive concept, typically including:
- Active ingredient definition: chemical structure, salt form, polymorph, or stereochemistry as explicitly claimed.
- Composition/formulation: excipient selection, ratio ranges, particle size, solubility-enabling components, or dosage unit definition.
- Manufacturing steps: process sequence and parameter windows (temperature, solvent systems, pH, crystallization conditions).
- Therapeutic use: indication wording, patient criteria, dosing frequency, and dose magnitude windows.
If a competitor changes a single claim-critical limiter (e.g., salt form, polymorph, excipient set, or dose regimen), they can move out of literal scope and into a potential equivalents analysis zone. CN equivalents doctrine in China exists but claim language still dominates entry strategy.
How does the claim set narrow to specific embodiments?
In CN drug patents, dependent claims often map to:
- Specific salt forms or solid-state forms (polymorphs/hydrates).
- Specific formulation embodiments (tablet/capsule/injectable; excipient system; ratio).
- Specific dosing regimens (mg/kg, mg/day, once/twice daily; treatment length).
- Specific comparative or diagnostic conditions that determine when the regimen applies.
From a landscape perspective, dependent-claim narrowing creates a “cluster” of enforceable embodiments around the patent’s preferred examples. Competitors can target entry by selecting a variant that omits one or more narrow features while keeping the active ingredient equivalent (if the independent claim already covers that active form broadly) or by selecting a different active form (if the patent’s independence hinges on the active definition).
What is the competitive relevance inside China’s patent landscape?
CN107075516 sits within a broader Chinese patent ecosystem where:
- Primary drug patents (composition and method-of-treatment) often control early generic entry.
- Formulation and solid-state patents can extend exclusivity even after core composition coverage.
- Combination patents limit entry if the claimed inventive concept includes a specific combination ratio or regimen.
For investors and R&D teams, the practical question is whether CN107075516 is:
- A core composition bottleneck (hard to design around), or
- A narrow formulation/indication bottleneck (design-around is often possible via alternative formulation, dosing, or indication positioning).
How to assess freedom-to-operate risk for CN107075516
A defensible FTO workflow for CN107075516 turns into three checks:
-
Claim-to-product mapping
- Identify whether the marketed or pipeline product uses the same active ingredient entity (including salt/polymorph/stereochemistry if claimed).
- Confirm formulation components and ratios if a composition/formulation claim exists.
- Confirm dosing regimen and indication wording if treatment-use claims exist.
-
Literal infringement triggers
- Any mismatch with an explicit numeric range or parameter window (dose, excipient ratio, processing condition) can reduce literal infringement risk.
- Any mismatch with explicit salt/polymorph identifiers can move out of literal coverage.
-
Design-around feasibility
- If the patent is driven by excipient system, changing formulation can work.
- If the patent is driven by solid-state form, selecting another polymorph or salt can work.
- If the patent is driven by dosing and indication, shifting to an unclaimed regimen or indication can reduce risk.
What does the broader patent landscape typically include around this type of filing?
Even when the claim set of a single CN publication is narrow, the enforcement landscape in China often includes:
- Family members filed in other jurisdictions that influence amendment strategy and claim narrowing.
- Related CN applications (divisional/national-phase continuations) that cover alternative embodiments.
- Patent thickets from follow-on reformulations (e.g., different salts, polymorphs, or dosage forms).
- Regulatory data exclusivity and patent linkage effects that determine practical market entry timing.
How does CN107075516 affect generic or biosimilar timelines in China?
China’s patent linkage system uses listed patents to block marketing authorization for an infringing product. The practical impact of CN107075516 is determined by:
- Whether it is listed for the reference product in the Chinese patent linkage system.
- Whether an applicant’s Abbreviated New Drug Application (or equivalent pathway) would be found infringing based on claim mapping.
When a patent is a composition or method-of-treatment claim that matches standard clinical use, it tends to have higher linkage blocking power. When it is limited to a specific formulation or dose regimen, the blocking effect can be narrower and can be addressed by changing the formulation or labeling.
Where are the likely design-around opportunities?
Design-arounds most commonly succeed by breaking one of the claim limiters:
- Salt/polymorph swap if CN107075516 claims a specific solid-state form.
- Excipient system change if formulation claims require particular excipients and ratios.
- Dose regimen change if treatment claims specify exact dosing schedules and magnitudes.
- Indication labeling change if treatment-use claims restrict the wording to particular indications or patient criteria.
- Combination ratio change if the patent is tied to a specific combination dosing ratio.
These paths reduce literal infringement risk and create negotiation space in patent settlement frameworks.
Key Takeaways
- CN107075516 is claim-bounded: scope and enforceability depend on the specific structural/composition/use limiters in its independent and dependent claims.
- Landscape impact is determined by claim type: composition and method-of-treatment claims create stronger market-entry barriers than narrow formulation or regimen-limited claims.
- Design-around is often possible by changing one claim-critical limiter such as solid-state form, excipient system, dosing regimen, or indication language.
- China-specific linkage effect matters: enforcement leverage in practice depends on whether CN107075516 (or related family members) is listed and then successfully asserted in the patent linkage process.
FAQs
1) Does CN107075516 typically cover the active ingredient itself or only specific formulations?
CN drug patents commonly split coverage between active ingredient/composition claims and downstream formulation/use claims. The actual coverage for CN107075516 follows the limitations embedded in its independent claims and narrows through dependent claims.
2) Which claim elements most often determine generic design-around?
In China drug patents, the most frequent design-around levers are salt/polymorph identity, formulation excipient composition and ratios, and dosing regimen and indication language.
3) Can a different dosing schedule avoid infringement under method-of-treatment claims?
If method-of-treatment claims specify dosing frequency, dose magnitude, or regimen length as explicit limitations, changing those parameters can reduce literal infringement risk.
4) How does the CN patent linkage system change the commercial impact of CN107075516?
Commercial impact depends on whether the patent is listed for the reference product and whether the generic applicant’s proposed product is mapped to infringing claim limitations.
5) Are dependent claims strategically important for competitors?
Yes. Dependent claims narrow enforceable embodiments and can define both (i) which specific variants are at risk and (ii) which “nearby” variants remain entry options.
References
[1] CN107075516. Chinese Patent Publication.
